ProclaRx names Doug Martin COO

Biotechnology company ProclaRx named a new COO Aug. 17 as it continues to make changes to its executive team.

Doug Martin, who has assumed the position effective immediately, will be responsible for the strategic planning, compliance and coordination of R&D, the company said in a statement.

ProclaRx, based in Columbus, Ohio, works to eliminate the causes of chronic and recurrent human infections.

Before joining ProclaRx, Martin was the director of corporate strategy at Applied Bio Ventures. He was responsible for developing and implementing corporate structures that effectively funded the acquisition and development of biopharmaceutical intellectual property.

Prior to Applied Bio Ventures, Martin was the vice president and assistant general counsel of regulatory legal and government relations at the Fireman’s Fund Insurance Company, a subsidiary of Allianz Global Corporate & Specialty.

"I am honored to join the ProclaRx team of experienced scientists, researchers, and drug commercialization experts whose singular vision is to efficiently and effectively help children and adults with chronic and intractable infections," Martin said in a statement.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.